NeuroPace (NPCE)
(Delayed Data from NSDQ)
$14.01 USD
-0.09 (-0.64%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $13.98 -0.03 (-0.21%) 6:36 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
NPCE 14.01 -0.09(-0.64%)
Will NPCE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NPCE
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates
Other News for NPCE
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
Wells Fargo upgrades NeuroPace to Overweight, raises price target to $20
Wells Fargo gets more bullish on NeuroPace, upgrades shares